NCT02530047View on ClinicalTrials.gov

Mesenchymal Stem Cells (MSC) for Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 16, 2016

Primary Completion Date

June 13, 2019

Study Completion Date

June 13, 2019

Conditions
Ovarian Cancer
Interventions
GENETIC

MSC-INFβ

"MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion.~Starting dose: 10\^5 MSC/kg once a week for 4 treatments."

BEHAVIORAL

Questionnaires

Symptom questionnaire completed once a week for 4 weeks.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT02530047 - Mesenchymal Stem Cells (MSC) for Ovarian Cancer | Biotech Hunter | Biotech Hunter